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httpcense.Abstract Background: Adiponectin (APN) is a secretory protein synthesized by adipocytes and
plays a potential role in regulating the inﬂammatory response by many of autocrine or paracrine.
The mechanism of APN participation in the inﬂammation of COPD remains unknown. So, we
investigated serum and induced sputum adiponectin as a biomarker of systemic inﬂammatory
response and to ﬁnd its relation with other inﬂammatory biomarkers like, IL-8, IL-6 and TNF-
a. The aim of the work was also to ﬁnd out its role in the pathogenesis of cachexia in COPD
patients.
Patients and methods: The study included 80 subjects including 60 COPD patients (20 stable and
40 exacerbated) and 20 age and sex-matched healthy control subjects. The adiponectin, interleukin-
8, interleukin-6 and tumor necrosis factor-alpha levels were measured in serum, induced sputum by
enzyme-linked immunosorbent assay. Serum CRP level was measured using the nephelometric
method. Body mass index (BMI) was estimated for COPD patients and its relation to the inﬂam-
matory biomarkers was studied.96450083.
(N.A.Mohamed),m.ahm84@
y@gmail.com (R. Elgamry),
aledabdelaziz_1@hotmail.com
e Egyptian Society of Chest
g by Elsevier
ng by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and Tuberculosis.
://dx.doi.org/10.1016/j.ejcdt.2013.03.005
46 N.A. Mohamed et al.Results: Adiponectin levels in COPD patients were signiﬁcantly higher than those in control sub-
jects (P< 0.001). CRP, APN, IL-8, IL-6, TNF-a were signiﬁcantly higher in the exacerbated
COPD patients compared to the stable group (P< 0.001, P< 0.001, P< 0.001, P< 0.001 and
P< 0.001, respectively). The ratio of APN level in serum to induced sputum was (3.1) in AECOPD
patients and (2.4) in stable COPD patients while for IL-8, IL-6 & TNF-a the ratios were all <(1).
Conclusion: Adiponectin could play a role as a biomarker of systemic inﬂammatory response in
COPD patients. Also, its rise in the exacerbation period denotes that this may also be a biomarker
of the exacerbation phase. While IL-8, IL-6, TNF-a could be used to reﬂect the airway inﬂamma-
tion in induced sputum. Adiponectin serum level is higher in underweight COPD patients which
may reﬂect its role in the pathogenesis of cachexia in COPD patients.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is considered
to be a chronic non-speciﬁc inﬂammation, which occurs in
the airways, lung parenchyma and pulmonary vessels. This
can cause the activation of inﬂammatory cells and the release
of various inﬂammatory mediators such as IL-8, IL-6 and
TNF-a. They can destroy the lung structure and promote the
inﬂammatory response of neutrophils [1]. Adiponectin (APN)
is one of the cytokines mainly secreted by adipose tissue [2].
Miller et al. [3] reported that the epithelial cells can also se-
crete APN which plays a potential role in regulating the
inﬂammatory response by many of autocrine or paracrine.
Other authors like Desruiseaux et al. [4] reported that
adiponectin is a secretory protein synthesized by adipocytes
and has important anti-inﬂammatory as well as anti-astheo-
sclerotic and anti-obesity effects.
Also, Lago et al. [5] reported that adiponectin has a wide
range of effects in pathologies with immune and inﬂammatory
components such as, cardiovascular disease, type 2 diabetes
mellitus, metabolic syndrome and rheumatoid arthritis.
The mechanism of APN participation in the inﬂammation
of COPD is still a point of debate.
Aim of the work
Is to demonstrate the validity of serum APN as a biomarker of
systemic inﬂammatory response in COPD patients and to
study the association between serum APN and other inﬂam-
matory markers (IL-8, IL-6, TNFa) in both serum and in-
duced sputum of COPD patients. The aim of the work was
also, to study relation of serum level of APN with BMI in
COPD patients in a trial to deﬁne its role in the pathogenesis
of cachexia in those patients.Patients and methods
Patients
This study included 60 COPD patients (40 exacerbated COPD
and 20 stable COPD) and another 20 age and sex matched
healthy control personnel. This study is carried out in the period
from January 2012 to December 2012 in chest outpatient clinic
and inpatient of Chest Department, Zagazig University
Hospitals.We excluded cases of concomitant confounding diseases
such as, malignancy, cardiac failure, endocrine disorders,
hepatic or renal diseases, systemic autoimmune or connective
tissue disorders and recent surgery.
Methods
All cases were subjected to the following :
(1) Complete history taking.
(2) General and local chest examination.
(3) Chest X-ray PA view.
(4) Diagnosis of COPD according to Global Initiative for
chronic obstructive lung disease (GOLD) criteria:
(NHLBI/WHO (GOLD), update) [6], so, 20 patients
had clinically stable COPD for at last 3 months, while
40 patients had clinical signs of COPD exacerbation
which are according to GOLD [6] criteria (increased
dyspnea, sputum production or sputum, purulence).
(5) Dyspnea score was determined according to the Medical
Research Council Scale (MRCS). The scale consists of
ﬁve items, the patients were categorized into the most
appropriate grade between 0 and 4 deﬁning their respira-
tory distress [7].
(6) Body weight and height were measured and body mass
index (BMI) was calculated as weight/(height)2 (kg/m2)
in both groups [8].
(7) Pulmonary function tests: All patients underwent spiro-
metric PFT with reversibility testing after inhalation of
short acting B2-agonist equivalent to 200 lg salbutamol
by a metered-dose inhaler. PFT were done using ZaN-
100 (ﬂow HANDY II) pulmonary function apparatus.
Forced vital capacity (FVC) and forced expiratory vol-
ume in 1 s (FEV1) were measured and were expressed
as percentage of predicted normal reference values.The
highest value from at least three spirometeric maneuvres
was used. Patient severity was determined as:
(1) FEV1 <50% predicted value were considered to
have severe/very severe COPD (40 patients).
(2) Those with FEV1 between 50% and 80% as mod-
erate COPD (8 patients).
(3) Those with FEV1 >80% as mild COPD (12 pat-
ients).According to NHLBL/WHO (GOLD) [6].(8) Samples of induced sputum: the samples were collected
from the subjects at 8 am after doing PFTs. All the sub-
jects must be conﬁrmed that they rinsed their mouths
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was inhaled with 3% hypertonic saline for 15 min using
Jet nebulizer. Then the sputum was forcefully coughed
to the Petri dish. The sputum was mixed up with 0.1%
dithiothreitol (Shanghai Huamei Biotechnology Com-
pany) by the volume ratio of 1:4 after the 37 C water
bath for 10 min and centrifugation was done. The spu-
tum supernatant was placed in a 70 C refrigerator
and preserved for measurement of cytokines.
(9) Determination of serum and induced sputum level of
APN, IL-8, IL-6, TNF-a and serum CRP:Tabl
Age
BMI
Adip
IL-8
Inter
TNF
* Sig
** H(a) Blood samples were collected by venipuncture i-
nto plain tubes. Sera were obtained by centrifu-
gation at 1000g for 5 min at room temperature.
The samples were stored at 70 C until analysis.
(b) The kit used in this study was produced by R & D
company, USA. Quantitative double antibody S-
andwich enzyme immune assay technique (ELIS-
A) was performed to detect the concentrations of
APN, IL-8, IL-6 and TNF-a in the serum and i-
nduced sputum.
(c) Serum CRP levels were measured with a commer-
cially available kit by nephelometry (Seac, Flo-
ransa, Italy). The nephelometric method assesses
agglutination of latex particles coated with anti-
body to CRP (Lower detection limit >2 mg/L)
[9].Statistical analysis
Data checked, entered and analyzed by using SPSS version 19.
Data were expressed as mean ± SD for quantitative variables.
t-Test and ANOVA were used when appropriate P< 0.05 was
considered statistically signiﬁcant.
Results
This study was designed to evaluate the role of adiponectin as
a biomarker of systemic inﬂammatory response in COPD pa-
tients and also, to study its association with other several
inﬂammatory markers (like, IL-8, IL-6 & TNF-a) in both ser-
um and induced sputum. Table 1 shows statistically signiﬁcant
difference in the mean serum level of APN, IL-8, IL-6, TNF-a
between COPD and control groups.
Table 2 detects, a signiﬁcant decrease in the exacerbated
group than in the stable group as regards mean FEV1% ande 1 Study of both demographic and mean serum levels of the
COPD patients
(n= 60) Mean ± SD
(years) 66.7 ± 6.9
(kg/m2) 25.3 ± 3.0
onectin (ng/ml) 14.54 ± 7.6
(pg/ml) 44.06 ± 7.8
leukin-6 (pg/ml) 16.5 ± 6.5
-a (pg/ml) 30.58 ± 5.5
niﬁcant.
ighly signiﬁcant.mean FEV1/FVC ratio. Also, dyspnea score was (3.6) in
COPD exacerbation and (1.3) in stable COPD (means signiﬁ-
cant increase of dyspnea score in COPD exacerbation.
Table 3 shows a signiﬁcant increase in mean serum levels of
APN, IL-8, IL-6, TNF-a and CRP in the exacerbated COPD
than in the stable COPD, also, in Table 4 there is a signiﬁcant
increase in mean serum levels of the same markers among se-
vere COPD cases than mild and moderate cases.
Table 5 shows a signiﬁcant increase in mean levels of APN,
IL-8, IL-6, TNF-a in the induced sputum of AE COPD than in
stable COPD.
Table 6 illustrates that the ratio of APN in serum to in-
duced sputum is highly signiﬁcant in the exacerbated COPD
than stable COPD indicating that, it has a role as a systemic
inﬂammatory biomarker in the exacerbation phase.
Table 7 detects a signiﬁcant increase in APN, IL-8, IL-6,
TNF-a in cases with dyspnea score more than (2). This means
that, these biomarkers increase with resp. distress and during
exacerbation of COPD.
Table 8 shows that adiponectin and TNF-a were signiﬁ-
cantly higher in COPD patients who were underweight
(BMI < 20). This indicates their sharing in the pathogenesis
of cachexia of COPD patients.
There is no difference in BMI or age between the COPD
and control groups (both groups are matched regarding age
and BMI). There is a signiﬁcant difference in mean serum lev-
els of APN, IL-6, IL-8 and TNF-a between COPD and control
groups being higher in COPD patients.
This table shows a signiﬁcant decrease in the exacerbated
group than in the stable group as regards mean FEV1%, mean
FEV1/FVC. Also, mean dyspnea score was 3.61 in COPD
exacerbation but is 1.3 in stable COPD (means a signiﬁcant in-
crease in dyspnea score in COPD exacerbation).
Mean serum level of CRP, adiponectin, IL-8, IL-6 and
TNF-a is signiﬁcantly higher in the exacerbated COPD pa-
tients compared to the stable group.
This table shows a statistically high signiﬁcant difference
between mild, moderate and severe COPD patients regarding
mean serum levels of APN, IL-8, IL-6 and TNF-a being higher
in the moderate and severe groups.
There is a highly signiﬁcant difference between COPD exac-
erbation and stable COPD as regards mean values of adipo-
nectin, IL-8, IL-6, TNF-a in induced sputum.
This table illustrates that the ratio of APN in serum to in-
duced sputum is highly increased in exacerbated COPD than
stable COPD indicating that, it has a role as a systemic inﬂam-
matory biomarker while other biomarkers, their serum/in-
duced sputum ratios are reversed (less than 1).inﬂammatory biomarkers in COPD patients and the controls.
Control (n= 20) Mean ± SD P-value
62.72 ± 4.2 0.09 NS
26.4 ± 4.0 0.36 NS
6.55±.3 <0.001**
23.95 ± 13.18 0.04*
9.73±.8 <0.001**
16.10 ± 4.5 <0.001**
Table 2 Demographic parameters in exacerbated COPD in comparison with stable COPD patients.
Exacerbated COPD
(n= 40)
Stable COPD
(n= 20)
P-value
Mean ± SD Mean ± SD
Age (years) 68.32 ± 6.6 64.4 ± 5.6 0.08 NS
BMI (kg/m2) 20.99 ± 5.2 24.33 ± 3.7 0.068 NS
FEV1% 55.28 ± 24 71.52 ± 22 0.03
*
FEV1/FVC 47.13 ± 9.2 63.12 ± 13 0.015
*
Dyspnea score 3.61±.2 1.3 ± 1.4 0.002*
Table 3 Serum inﬂammatory biomarkers in exacerbated and stable COPD groups.
Exacerbated COPD (n= 40) Stable COPD (n= 20) P-value
Mean ± SD Mean ± SD
CRP (mg/dl) 28.15 ± 4.5 8.35 ± 21 <0.001**
Adiponectin (ng/ml) 18.33 ± 1.9 10.63 ± 3.1 <0.001**
IL-8 (pg/ml) 81.52 ± 9.2 44.22±.4 <0.001**
Interleukin-6 (pg/ml) 34.42 ± 9.1 16.51 ± 6.1 <0.001**
TNF-a (pg/ml) 80.41 ± 13 32.62 ± 5.3 <0.001**
Table 4 Serum inﬂammatory biomarkers in different stages of COPD severity.
Mild COPD (n= 12) Moderate COPD (n= 8) Severe COPD (n= 40) P-value
Mean ± SD Mean ± SD Mean ± SD
APN 8.51 ± 2.2 14.41 ± 3.3 19.41 ± 8.4 <0.001**
IL-8 41.25 ± 6.1 61.15 ± 7.4 82.11 ± 18.2 <0.001**
IL-6 15.52 ± 3.1 24.31 ± 6.2 35.41 ± 7.1 <0.001**
TNF-a 20.59 ± 4.2 55.51 ± 8.1 80.42 ± 12 <0.001**
Table 5 The concentrations of APN, IL-6, IL-8 and TNF-a in induced sputum of both exacerbated and stable COPD patients.
COPD exacerbation (n= 40) Stable COPD (n= 20) P-value
Mean ± SD Mean ± SD
Adiponectin (ng/ml) 6.23 ± 1.7 3.51 ± 1.2 <0.001**
IL-8 (pg/ml) 445.32 ± 160.1 170.44 ± 60.71 <0.001**
Interleukin-6 (pg/ml) 185.43 ± 1.8 112.9 ± 9.6 <0.001**
TNF-a (pg/ml) 135.62 ± 1.4 56.48 ± 14.1 <0.001**
Table 6 Ratios of serum to induced sputum values of inﬂammatory biomarkers in exacerbated and stable COPD patients.
APN IL-8 IL-6 TNF-a
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
AECOPD 3.1 ± 1.1 0.0009 ± 0.0001 0.19 ± 0.01 0.59 ± 0.02
Stable COPD 2.4 ± 0.9 0.24 ± 0.01 0.083 ± 0.002 0.36 ± 0.01
P-value <0.001 <0.001 <0.001 <0.01
Table 7 Relation between dyspnea score & mean serum values of the studied inﬂammatory biomarkers in COPD patients.
Dysp. score APN IL-8 IL-6 TNF-a
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
<2 9.88 ± 2.1 42.2 ± 5.1 14.33 ± 6.2 30.55 ± 4.4
>2 17.51 ± 6.7 79.41 ± 17.1 31.22 ± 7.3 81.42 ± 15
P-value <0.001** <0.001** <0.001** <0.001**
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Table 8 Relation of body mass index to mean serum values of
the studied inﬂammatory biomarkers in COPD patients.
BMI APN IL-8 IL-6 TNF-a
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
<20 15.23 ± 4.7 42.2 ± 8.3 14.37 ± 1.8 33.8 ± 1.1
20–24.9 13.1 ± 3.9 41.5 ± 7.2 14.35 ± 2.2 31.9 ± 3.1
25–29.9 9.81 ± 2.8 41.3 ± 6.9 14.32 ± 3.1 30.7 ± 1.7
P30 9.21 ± 4.6 40.9 ± 7.2 13.9 ± 3.6 28.6 ± 2.1
P-value 0.01 0.9 0.98 0.008*
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cases with dyspnea score more than 2. This indicates that these
biomarkers increase with increasing dyspnea & distress that
occur in AECOPD.
Adiponectin and TNF-a are signiﬁcantly higher in COPD
patients who are underweight (BMI < 20). This indicates their
sharing in cachexia of COPD patients.
Discussion
The inﬂammation in the airways leads to the main pathologi-
cal process of COPD [10]. COPD is also a kind of systemic
inﬂammatory disease [11] and is characterized with the abnor-
mal activation of inﬂammatory cells and the abnormal increase
of circulating cytokines including CRP, IL-8, TNF-a and IL-6.
Adiponectin is a newly discovered cytokine [12]. IL-8, IL-6,
TNF-a and APN were highly expressed in bronchoalveolar la-
vage ﬂuid (BALF) of COPD patients. Among whom the level
of APN was the highest? APN in the BALF of COPD patients
was 3–5 times than that in healthy control subjects. Because of
the unacceptance of ﬁberoptic bronchoscopy in getting BALF,
induced sputum was collected instead in this study. Another
study reported that COPD patients had increased APN level
in the plasma and the level was related to elevated TNF-a
and IL-6 [13].
Also, another study reported that, the adipose tissue is an
important contributor to the systemic manifestation of COPD.
Indeed, the inﬂammatory/anti-inﬂammatory effects of adipo-
kines highlight the fact that adipose tissue is more than an en-
ergy storage organ; they also highlighted the importance of
body composition in the pathogenesis of COPD [11]. The pre-
cise mechanism of malnutrition in COPD has not yet been
clariﬁed. Tomada et al. [14] also found that serum levels of
the anti-obesity adipokine adiponectin were signiﬁcantly high-
er even in COPD patients with normal BMI than levels in
healthy subjects indicating that adiponectin levels rise earlier
than body weight loss as a component of the systemic inﬂam-
matory response and consequently may contribute to the
development of malnutrition.
So, this study was designed to elucidate the validity of ser-
um adiponectin as a biomarker of systemic inﬂammatory re-
sponse in COPD patients and to study the association
between serum adiponectin and other inﬂammatory markers
(TNF-a, IL-8, IL-6, CRP) in both serum and induced sputum.
The aim of this study was also to study relation of serum level
of adiponectin with BMI in a trial to deﬁne its role in the path-
ogenesis of cachexia in COPD patients.
In Table 1, there is no difference in BMI or age between the
COPD and control groups.In the present study, there is a signiﬁcant increase in APN,
interleukin-6, interleukin-8, TNF-a in COPD compared to
that in control group (Table 1). These results agree with Kirdar
et al. [12].
Tomada et al. [14] and Kirdar et al. [12], detected, that
adiponectin level was approximately 2-fold higher in normal
weight, stable COPD patients than in control. This result
can be explained by the increase in respiratory effort that cor-
relates with the overload of respiratory muscles and excess
respiratory exercise [14]. Previous studies have revealed that
chronic exercise increases plasma adiponectin levels and en-
hances expression of adiponectin receptor-1 in skeletal muscles
[15].
Adiponectin receptor-1 promotes glucose uptake and lipid
oxidation in the muscle [16]. The persistent excess respiratory
exercise caused by hyperinﬂation elevates plasma adiponectin
levels before body weight loss [14]. Also in the same table there
is a signiﬁcant increase of IL-8, IL-6 and TNF-a due to abnor-
mal activation of inﬂammatory cells and the abnormal increase
of circulating cytokines.
In Table 2 there is a signiﬁcant decrease in FEV1 and FEV1/
FVC in exacerbated COPD patients than stable COPD pa-
tients, also, there is an increase in dyspnea score in exacerbated
COPD patients than stable COPD patients.
These results are in line with Kirdar et al. [12] who illus-
trated that this is an indicator of respiratory muscle distress
and match with the deﬁnition of AE-COPD introduced by
GOLD [17].
In Tables 3 and 4, there is a signiﬁcant increase in the serum
level of CRP, adiponectin, IL-8, IL-6 and TNF-a in COPD
exacerbated patients than stable COPD patients. These inﬂam-
matory biomarkers are also signiﬁcantly elevated in the serum
of severe COPD than mild and moderate COPD. Xie et al. [13]
reported that the concentration of APN in the serum or in-
duced sputum in AECOPD patients were signiﬁcantly higher
than those in stable COPD patients (P< 0.01). Also, APN
was positively correlated with IL-8 and TNF-a in the serum
and induced sputum (P< 0.05). APN was also, positively cor-
related with IL-8 and TNF-a in the serum and induced sputum
(r= 0.751, 0.659, 0.707 and 0.867 respectively, P< 0.05).
Ehling et al. [15] explained that, the main cytokines in-
volved in the inﬂammation of COPD are IL-8, TNF-a and
IL-6. Among them, IL-8 is the most important which can acti-
vate neutrophils and cause degranulation. Otero et al. [18] and
Wert [19] illustrated that, various inﬂammatory mediators are
released in the degranulation, promoting inﬂammatory reac-
tion. Epithelial cells in the airways will stimulate the expression
of IL-8 under APN control, suggesting a potential pro-inﬂam-
matory role of APN. TNF-a is an important inﬂammatory
mediator produced by several kinds of cells, playing a role in
activating the neutrophils and stimulating the release of IL-8.
Its over-expression can lead to the chronicity of inﬂammatory
response and the aggravation of lung injury [11].
In our study, there is elevated concentration of APN, IL-8,
IL-6 and TNF-a in the serum and induced sputum of COPD
patients especially exacerbated COPD (Tables 3 and 5), indi-
cating that APN and inﬂammatory mediators were inter-regu-
lated. It suggests that APN could be a new marker of COPD
inﬂammation.
In Table 5, there is a signiﬁcant increase in induced sputum
APN, IL-8, IL-6 and TNF-a in COPD exacerbation than in
stable COPD. This result is concomitant with Krommidas
50 N.A. Mohamed et al.et al. [20] who reported that, adiponectin is associated with the
systemic inﬂammatory process during exacerbation of COPD.
They also reported that the most signiﬁcant associations seem
to be with IL-6 and TNF-a.
Also, Xie [13] reported that IL-8, IL-6, TNF-a are mainly
secreted in the airways by the inﬂammatory cells. However,
APN is mainly secreted by fat cells and released into blood
and its secretion by airway epithelial cells plays a less impor-
tant role [21].
Table 6 revealed that the ratios of APN level in serum to
induced sputum was (3.1) in AE COPD patients and (3.4) in
stable COPD patients while for IL-8, IL-6, TNF-a the ratios
were all <(1).
This result is in line with Xie [13] who reported that the ra-
tios of APN level in serum to induced sputum 2.85 in AE
COPD and 3.03 in stable COPD patients while for IL-8,
TNF-a and IL-6 the ratios were all less than (1), all these re-
sults indicate that the concentration of APN in blood could
better reﬂect systemic inﬂammation of COPD while concentra-
tion IL-8, TNF-a & IL-6 in induced sputum could better re-
ﬂect airway inﬂammation.
Table 7 shows a signiﬁcant increase of APN, IL-8, IL-6,
TNF-a in cases with dyspnea score more than 2, this indicated
that APN, IL-8, IL-6 & TNF-a can be used as inﬂammatory
biomarkers to indicate respiratory distress especially in AE
COPD patients. This result is concomitant with Kirdar et al.
[12].
Table 8 shows that adiponectin and TNF-a were signiﬁ-
cantly high in COPD patients with underweight (BMI < 20).
This result can be explained by Wouter et al. [11] who stated
that, adiponectin levels rise earlier than body weight loss as
a component of the systemic inﬂammatory response and con-
sequently may contribute to the development of malnutrition.
Conclusion
APN could play a role as a new biomarker of systemic inﬂam-
mation among COPD patients especially in serum. While IL-8,
IL-6, TNF-a could better reﬂect the airway inﬂammation in in-
duced sputum. Also adiponectin serum level is higher in under-
weight COPD patients which may reﬂect its role in the
pathogenesis of cachexia in COPD patients.
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